GYA-01

N/A

Report date: 2026/03/16 20:01:47
First In Class

Base Information

Drug NameGYA-01
Drug Alias NameGYA-01GYA01
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionLeukocyte Antigen CD84 modulatorsT lymphocyte replacements
TargetsLeukocyte Antigen CD84
Therapy Area/IndicationsLeukemia, Myeloid, AcutePrecursor T-Cell Lymphoblastic Leukemia-LymphomaLeukemia, T-Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySpain
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesGyala Therapeutics SL
China Registration ClassN/A

Develop Information

Active CompaniesGyala Therapeutics SLGyala Therapeutics
Inactive CompaniesN/A
Active IndicationsLeukemia, Myeloid, AcutePrecursor T-Cell Lymphoblastic Leukemia-LymphomaLeukemia, T-Cell
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A